[
    [
        {
            "time": "",
            "original_text": "健帆生物：肾病领域确定性强，肝病领域成长可期",
            "features": {
                "keywords": [
                    "健帆生物",
                    "肾病领域",
                    "确定性强",
                    "肝病领域",
                    "成长可期"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "健帆生物：肾病领域确定性强，肝病领域成长可期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]